Dipeptidyl-Peptidase IV Inhibitors: all 899 studies that test it

Page 4 of 9. Open to participants first (28), then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.CompletedNCT00755846Phase 2Results posted
• BI 10773 add-on to Metformin in Patients With Type 2 DiabetesCompletedNCT00749190Phase 2Results posted
• A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is InappropriateCompletedNCT00740051Phase 3Results posted
• A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)CompletedNCT00730275Phase 1Results posted
• Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a ThiazolidinedioneCompletedNCT00729326Phase 4Results posted
• MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)CompletedNCT00722371Phase 3Results posted
• The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic PatientsCompletedNCT00716092Phase 2Results posted
• Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly DiabeticsCompletedNCT00707993Phase 3Results posted
• Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)CompletedNCT00704132Phase 1Results posted
• A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)CompletedNCT00701090Phase 3Results posted
• The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes MellitusCompletedNCT00700817Phase 3Results posted
• Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic ControlCompletedNCT00698932Phase 3Results posted
• Sitagliptin in Combination With Metformin and SulfonylureaCompletedNCT00686634Phase 4Results posted
• Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR AloneCompletedNCT00683657Phase 3Results posted
• Effects of Glutamine on GLP-1 and Insulin Secretion in ManCompletedNCT00673894Not applicableResults posted
• 18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)CompletedNCT00666458Phase 3Results posted
• Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 DiabetesCompletedNCT00661362Phase 3Results posted
• Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 DiabetesCompletedNCT00660075Phase 3Results posted
• The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic SubjectsCompletedNCT00659711Not applicableResults posted
• Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart FailureCompletedNCT00657280Early Phase 1Results posted
• Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.CompletedNCT00655863Phase 3Results posted
• Japanese P III vs Voglibose and PlaceboCompletedNCT00654381Phase 3Results posted
• Efficacy vs Placebo as Initial Combination Therapy With PioglitazoneCompletedNCT00641043Phase 3Results posted
• A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)CompletedNCT00631488Phase 2Results posted
• Efficacy and Safety Study of MP-513 in Patients With Type 2 DiabetesCompletedNCT00628212Phase 2Results posted
• Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT00622284Phase 3Results posted
• Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic ControlCompletedNCT00621140Phase 3Results posted
• Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal ImpairmentCompletedNCT00614939Phase 3Results posted
• BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 DiabetesCompletedNCT00602472Phase 3Results posted
• Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 DiabetesCompletedNCT00601250Phase 3Results posted
• 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension PeriodCompletedNCT00575588Phase 3Results posted
• Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)CompletedNCT00541775Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)CompletedNCT00541450Phase 3Results posted
• Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)CompletedNCT00541229Phase 1Results posted
• MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)CompletedNCT00532935Phase 3Results posted
• Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)CompletedNCT00511108Phase 1Results posted
• Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)CompletedNCT00509262Phase 3Results posted
• Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)CompletedNCT00509236Phase 3Results posted
• MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)CompletedNCT00482729Phase 3Results posted
• Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)CompletedNCT00449930Phase 3Results posted
• Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes MellitusCompletedNCT00432276Phase 3Results posted
• Beta-Cell Function and Sitagliptin Trial (BEST)CompletedNCT00420511Phase 2Results posted
• A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)CompletedNCT00411554Phase 3Results posted
• Long Term Effects of DPP-IV Inhibitor Treatment in Patients With Type 2 DiabetesCompletedNCT00411411Phase 3Results posted
• Initial Combination With Pioglitazone Study (0431-064)CompletedNCT00397631Phase 3Results posted
• Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes MellitusCompletedNCT00395512Phase 3Results posted
• Sitagliptin Added-on to Insulin Study (0431-051)CompletedNCT00395343Phase 3Results posted
• A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and ExerciseCompletedNCT00374907Phase 3Results posted
• MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)CompletedNCT00372060Phase 3Results posted
• Incretins in Impaired Fasting GlucoseCompletedNCT00364377Phase 4Results posted
• Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)CompletedNCT00350779Phase 3Results posted
• Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes MellitusCompletedNCT00337610Phase 3Results posted
• Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.CompletedNCT00328627Phase 3Results posted
• Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes PatientsCompletedNCT00328172Phase 2Results posted
• A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and ExerciseCompletedNCT00327015Phase 3Results posted
• Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and ExerciseCompletedNCT00316082Phase 3Results posted
• A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With SulfonylureasCompletedNCT00313313Phase 3Results posted
• Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 DiabetesCompletedNCT00309608Phase 2Results posted
• Long-term Safety of Alogliptin in Patients With Type 2 Diabetes MellitusCompletedNCT00306384Phase 3Results posted
• Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)CompletedNCT00305604Phase 3Results posted
• A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy AloneCompletedNCT00295633Phase 3Results posted
• MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)CompletedNCT00289848Phase 3Results posted
• Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes MellitusCompletedNCT00286494Phase 3Results posted
• Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.CompletedNCT00286468Phase 3Results posted
• Efficacy and Safety of Alogliptin in Subjects With Type 2 DiabetesCompletedNCT00286455Phase 3Results posted
• Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes MellitusCompletedNCT00286442Phase 3Results posted
• Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.CompletedNCT00286429Phase 3Results posted
• A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)CompletedNCT00127192Phase 2Results posted
• Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin AloneCompletedNCT00121667Phase 3Results posted
• Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and ExerciseCompletedNCT00121641Phase 3Results posted
• Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)CompletedNCT00106704Phase 3Results posted
• MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)CompletedNCT00103857Phase 3Results posted
• An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)CompletedNCT00095056Phase 3Results posted
• An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)CompletedNCT00094770Phase 3Results posted
• An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)CompletedNCT00094757Phase 3Results posted
• Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)CompletedNCT00087516Phase 3Results posted
• Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)CompletedNCT00086515Phase 3Results posted
• Pioglitazone Add-on Study in Patients With Type 2 Diabetes MellitusCompletedNCT00086502Phase 3Results posted
• Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release TabletsCompletedNCT07872358Phase 1
• Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fed Study.CompletedNCT07763964Not applicable
• Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fast Study.CompletedNCT07763951Not applicable
• Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fed Study.CompletedNCT07763912Not applicable
• Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fast Study.CompletedNCT07763899Not applicable
• Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release TabletsCompletedNCT07691203Phase 1
• Bioequivalence Study of Sitagliptin/Metformin Extended-Release Tablets in Healthy SubjectsCompletedNCT07679711Phase 1
• A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.CompletedNCT07567781Phase 1
• Dose Optimization of Sitagliptin and Duloxetine in Diabetic CirrhosisCompletedNCT07439536Phase 4
• A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting.CompletedNCT07399470Phase 1
• Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated TabletsCompletedNCT07213895Phase 1
• The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic RatsCompletedNCT07083232Phase 4
• Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk FactorsCompletedNCT07077525Phase 4
• To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.CompletedNCT07039890Phase 1
• Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes MellitusCompletedNCT06952231Phase 3
• Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated TabletsCompletedNCT06932159Phase 1
• Comparison of Once-Weekly Trelagliptin vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 DiabetesActive, not recruitingNCT06913101Not applicable
• Comparison of Once-Weekly Trelagliptin Vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 DiabetesActive, not recruitingNCT06889909Not applicable
• Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.CompletedNCT06851962Phase 4
• DPP4-Inhibitors and Bone Metabolism in DiabetesCompletedNCT06770894Phase 3
• Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With GlucotoxicityCompletedNCT06613750Phase 4
• The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and AlbuminuriaActive, not recruitingNCT06611904Not applicable

← Dipeptidyl-Peptidase IV Inhibitors overview